Atopic Dermatitis & Skin Infections Request More Information Trial Objective The purpose of this study is to learn more about skin cells and how they regulate the skin barrier. Studies indicate that those with atopic dermatitis and psoriasis may be more susceptible to bacterial infections. Our researchers will use samples from patients with atopic dermatitis, psoriasis and healthy people to examine the differences in their genes. Researchers also will be trying to determine if inflammation effects the function of skin cells. Enrollment New enrollment for this trial is temporarily paused Who Can Participate Adults with atopic dermatitis (eczema) or psoriasis, as well as adults with normal, healthy skin. Age: 18-65 Gender: Any Gender Estimated Time Commitment Up to 3 visits or approximately 3 hours × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Not Available Trial Contact For more information, contact: Shirley Palombi, RN 303.398.1409 Request More Information Trial Location National Jewish Main Campus, Denver, CO Principal Investigators Donald Leung, PhD, MD + × Donald Leung, PhD, MD Professor Head, Division of Pediatric Allergy & Immunology Department of Pediatrics View Full Profile Make an Appoinment Co-Investigators Elena Goleva, PhD + × Elena Goleva, PhD Associate Professor Department of Pediatrics View Full Profile Make an Appoinment Max Seibold, PhD + × Max Seibold, PhD Associate Professor Office of Academic Affairs Center for Genes, Environment & Health Department of Pediatrics View Full Profile Make an Appoinment Request More Information Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for this trial.